TY  - JOUR
AU  - Alors-Perez, Emilia
AU  - Blazquez-Encinas, Ricardo
AU  - Alcala, Sonia
AU  - Viyuela-Garcia, Cristina
AU  - Pedraza-Arevalo, Sergio
AU  - Herrero-Aguayo, Vicente
AU  - Jimenez-Vacas, Juan M.
AU  - Mafficini, Andrea
AU  - Sanchez-Frias, Marina E.
AU  - Cano, Maria T.
AU  - Abollo-Jimenez, Fernando
AU  - Marin-Sanz, Juan A.
AU  - Cabezas-Sainz, Pablo
AU  - Lawlor, Rita T.
AU  - Luchini, Claudio
AU  - Sanchez, Laura
AU  - Sanchez-Hidalgo, Juan M.
AU  - Ventura, Sebastian
AU  - Martin-Hijano, Laura
AU  - Gahete, Manuel D.
AU  - Scarpa, Aldo
AU  - Arjona-Sanchez, Alvaro
AU  - Ibanez-Costa, Alejandro
AU  - Sainz, Bruno, Jr.
AU  - Luque, Raul M.
AU  - Castano, Justo P.
PY  - 2021
DO  - 10.1186/s13046-021-02153-9
UR  - https://hdl.handle.net/10668/25886
T2  - Journal of experimental & clinical cancer research
AB  - Background Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, requiring novel treatments to target both cancer cells and cancer stem cells (CSCs). Altered splicing is emerging as both a novel cancer hallmark and an attractive...
LA  - en
PB  - Bmc
KW  - Pancreatic cancer
KW  - Splicing-spliceosome
KW  - Pladienolide-B
KW  - cancer stem cells
KW  - Differential expression analysis
KW  - Ductal adenocarcinoma
KW  - Apoptosis
KW  - Isoform
TI  - Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug
TY  - research article
VL  - 40
ER  -